<DOC>
	<DOCNO>NCT00421733</DOCNO>
	<brief_summary>The study objective evaluate safety paricalcitol capsule efficacy paricalcitol capsule albuminuria reduction patient Chronic Kidney Disease ( CKD ) Type 2 diabetic nephropathy receive optimal angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) therapy .</brief_summary>
	<brief_title>The Effect Paricalcitol Capsules Reducing Albuminuria Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Male female participant &gt; = 20 year old . Participant Type 2 Diabetes Mellitus treat least one antihyperglycemic medication within 12 month prior Screening Phase Participant receive stable dose ( i.e. , type regimen ) ACEi and/or ARB least three month prior Screening Phase . However , participant may switch different brand equivalent dos three month prior Screening Phase . Participant expect begin dialysis least 6 month . If female , participant breast feeding pregnant . For entry Treatment Phase , participant must satisfy follow criterion base Screening laboratory value : Estimated glomerular filtration rate ( GFR ) 1590 mL/min/1.73m2 simplify Modification Diet Renal Disease ( MDRD ) formula Urinary albumin creatinine ratio ( UACR ) 100 3000 mg/g determine mean three first morning void urine specimen obtain within one week Corrected serum calcium level &lt; = 9.8 mg/dL intact parathyroid hormone ( iPTH ) value 35500 pg/mL Glycosylated hemoglobin A1c ( HbA1c ) &lt; = 12 % Serum albumin &gt; 3.0 g/dL Negative urine pregnancy test female participant Participant previously prescriptionbased vitamin D therapy within six month prior Screening Phase . Participant history allergic reaction significant sensitivity paricalcitol drug similar study drug . Participant primary glomerulonephritis secondary nephritis addition diabetic nephropathy . Participant acute renal failure within 12 week Screening Phase , define acute rise ( &gt; = 0.5 mg/dL ) serum creatinine &gt; 4 mg/dL . Participant chronic gastrointestinal disease . Participant secondary hypertension . Participant poorly control hypertension . Participant history kidney stone . Participant history drug alcohol abuse within six month prior Screening Phase . Participant evidence poor compliance diet medication . Participant receive investigational drug within 30 day prior study drug administration . Participant take calcitonin , bisphosphonates , cinacalcet , glucocorticoid ( except topical glucocorticoid ) , drug may affect calcium , bone metabolism , calcium contain phosphate binder female participant stable ( dose product three month ) estrogen and/or progestin therapy . For reason , participant consider Investigator unsuitable candidate receive paricalcitol capsule put risk study procedure . Participant known human immunodeficiency virus ( HIV ) positive . Participant use know inhibitor inducer cytochrome P450 3A ( CYP3A ) within two week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Type 2 Diabetic Nephropathy</keyword>
</DOC>